1. Home
  2. KLTR vs LCTX Comparison

KLTR vs LCTX Comparison

Compare KLTR & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kaltura Inc.

KLTR

Kaltura Inc.

HOLD

Current Price

$1.57

Market Cap

238.4M

Sector

Technology

ML Signal

HOLD

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.65

Market Cap

407.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KLTR
LCTX
Founded
2006
1990
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
238.4M
407.7M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
KLTR
LCTX
Price
$1.57
$1.65
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$3.50
$4.25
AVG Volume (30 Days)
332.3K
1.1M
Earning Date
02-19-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$180,921,000.00
$10,816,000.00
Revenue This Year
$3.10
$6.32
Revenue Next Year
$1.08
$124.49
P/E Ratio
N/A
N/A
Revenue Growth
1.88
24.05
52 Week Low
$1.36
$0.37
52 Week High
$2.82
$2.09

Technical Indicators

Market Signals
Indicator
KLTR
LCTX
Relative Strength Index (RSI) 45.57 45.35
Support Level $1.64 $1.58
Resistance Level $1.73 $1.77
Average True Range (ATR) 0.07 0.08
MACD -0.01 -0.01
Stochastic Oscillator 11.11 28.57

Price Performance

Historical Comparison
KLTR
LCTX

About KLTR Kaltura Inc.

Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and at school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments which are Enterprise, Education, and Technology, and Media and Telecom. The majority of the revenue is derived from Enterprise, Education & Technology. The majority of the revenue is earned from the United States.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: